Optimizing Outcomes and Managing Adverse Events in CLL

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Introduction

Risk of Bleeding With Ibrutinib

Prevention and Management of Bleeding Risk

Suggestions for Management of Atrial Fibrillation Associated With Ibrutinib

Managing Treatment-Emergent Diarrhea in Patients With CLL

Managing Transaminitis Induced by Idelalisib

Managing Transaminitis Induced by Idelalisib (cont)

Treatment Modification in Relapse Setting

Challenges of Idelalisib as Frontline Therapy

Managing Idelalisib-Induced Colitis

Ibrutinib- and Idelalisib-Induced Pneumonitis

Tumor Lysis Syndrome Associated With Venetoclax and Ibrutinib

Recommended TLS Prophylaxis Based on Risk Group

Major Concern in the Management of TLS Faculty Recommendations

Cytopenias Associated With Ibrutinib

Management of Ibrutinib-Induced Cytopenias

Management of Cytopenias Associated With Venetoclax

Cytopenias Associated With Obinutuzumab

Prophylaxis for Idelalisib-Induced Infections in Patients With Relapsed/Refractory CLL

Infusion Reactions Induced by Obinutuzumab

Managing Infusion Reactions Induced by Obinutuzumab

Long-Term Complications

Long-Term Complications (cont)

Interprofessional Care

Best Practices for Communication Within a Team

Concluding Remarks

Abbreviations

Abbreviations (cont)